Table 2. Demographic and clinical characteristics of the subjects included in the study.
| Classification/group | NMG | TAMG |
|---|---|---|
| Gender | ||
| Female | 5 | 2 |
| Male | 4 | 7 |
| Age | 18–62 (mean 50.2, median 55) | 30–62 (mean 46, median 42) |
| WHO histologic classification | ||
| A | 1 | 1 |
| AB | 2 | – |
| B1 | 2 | – |
| B2 | 3 | 6 |
| B3 | 1 | 2 |
| MGFA classification | ||
| 1 | – | 1 |
| 2a | – | 2 |
| 2b | – | 3 |
| 3a | – | 3 |
| AChR antibody | ||
| Positive | – | 9 |
| Negative | – | 0 |
TAMG, thymoma-associated MG; NMG, non-MG thymoma; WHO, World Health Organization; MGFA, Myasthenia Gravis Foundation of America; AChR, acetylcholine receptor; MG, myasthenia gravis.